Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve.
The study will enrol patients between 18 and 35 years, treated with neoadjuvant or adjuvant
chemotherapy for systemic lupus erythematosus (Group 1), breast cancer (Group 2) or Hodgkin
disease (Group 3)to evaluate the clinical and biological markers of ovarian reserve. The
follow-up will last 24 months for each patients with a visit before treatment, and at 3
months, 6 months, one year and two years after treatment.
During this period, we will collect pre and post treatment clinical data,and biological data
and ultrasonographic data such as antral follicle count which is a marker of ovarian
follicle reserve.These data were not observed in current practice.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label
AMH level and antral follicle count
one year after the chemotherapy treatment
Renato Fanchin, MD
Assistance Publique - Hôpitaux de Paris Hôpital Antoine Béclère
France: Ministry of Health